Oxford Biomedica announces board changes
This article was originally published in Scrip
Executive Summary
The UK gene therapy company Oxford BioMedicahas announced that its chief executive officer, Dr Mike McDonald, has left the board. John Dawson, who was appointed non-executive director on August 1st, will take the position of acting CEO.